High carbohydrate antigen 125 (CA-125) level was reported to be associated with some cardiac dysfunctions, such as chronic heart failure, but the relationship between CA-125 level and coronary heart disease (CHD) risk remains unclear. The aim of this study was to explore the potential association in a Chinese older population.
In a population-based case-control study conducted in a Chinese older population, serum CA-125 levels were measured in 1177 diagnosed CHD patients and 3531 age and sex matched control subjects without CHD.
Serum CA-125 level was significantly higher in CHD patients than controls (P < 0.001) with adjustment for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction. CHD risk was doubled (OR: 2.10, 95%CI: 1.69-2.60) among subjects in the highest quartile compared to those in the lowest quartile of CA-125 level (Ptrend < 0.001). Furthermore, CA-125 levels were associated with CHD risks in subjects with age over 60 years (OR: 2.19, 95%CI: 1.75-2.73), current smokers (OR: 2.29, 95%CI: 1.50-3.49), current drinkers (OR: 2.35, 95%CI: 1.57-3.53) and subjects with hypertension (OR: 2.04, 95%CI: 1.71-2.43).
Citation: Li X, He M, Zhu J, Yao P, Li X, Yuan J, et al. (2013) Higher Carbohydrate Antigen 125 Levels Are Associated with Increased Risk of Coronary Heart Disease in Elderly Chinese: A Population-Based Case-Control Study. PLoS ONE 8(11): e81328. https://doi.org/10.1371/journal.pone.0081328
Editor: Yiqing Song, Brigham & Women's Hospital, and Harvard Medical School, United States of America
Received: September 3, 2013; Accepted: October 21, 2013; Published: November 26, 2013
Copyright: © 2013 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study is funded by the Huazhong University of Science and Technology Foundation for Educational Development and Research; the National Basic Research Program grant 2011CB503800, the Natural Scientific Foundation of China (NSFC-81172751), and the Dongfeng Motor Corporation (DMC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The study is funded by Dongfeng Motor Corporation (DMC). This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
CA-125 (Carbohydrate antigen 125) is a well-established tumor marker to monitor the efficacy of ovarian cancer therapy and early detect its recurrence . But it is also elevated in both ovarian and non-ovarian diseases, malignant and non-malignant conditions . Interestingly, there are evidences which showed that, CA-125 could be secreted from mesothelial cells as well as tumoural origin tissue [3,4]. Recent studies have also demonstrated that serum CA-125 level was significantly elevated in chronic heart failure patients [5-9]. Furthermore, increasing evidences have indicated that high serum CA-125 levels were associated with risk of hypertrophic cardiomyopathy, pseudoaneurysm of the left ventricular lateral wall, cardiac angiosarcoma, pericardial tamponade, infective perimyocarditis and atrial fibrillation [10-15]. However, few studies have investigated whether the higher concentration of serum CA-125 is associated with the increased risk of coronary heart disease (CHD) or not until now.
Coronary heart disease (CHD) is a condition in which there is an inadequate supply of blood and oxygen to a portion of the myocardium; it typically occurs when there is an imbalance between myocardial oxygen supply and demand. It is one of the leading causes of mortality and disability in both industrialized and developing countries [16-18]. It was estimated that heart disease and stroke are projected to be the single leading cause of death by 2030 . CHD is a multi-factorial disease and the underlying mechanisms of CHD have not been well elucidated clearly. Inflammation is considered to play an important role in the development of atherosclerosis [20,21]. Systemic inflammation could enhance atherogenesis and inflammatory components could drive the formation, progression and rupture of atherosclerotic plaques for inflammation could promote loss of endothelium, the hallmark of superficial erosion [22-25]. Previous studies have also found that CA-125 could be produced by mesothelial cells as a consequence of inflammation, stasis or other stimulatory mechanisms in patients with heart failure [5,6,9,26]. Recently, a small case-control study also suggested inflammation and cytokine levels may be responsible for CA-125 production and release . Given this evidence, it is reasonable to hypothesize that there may be a potential association between serum CA-125 level and CHD risk.
Here, we performed a large population-based case-control study to explore the association between serum CA-125 level and the CHD risk in Chinese older population, which was based on Dongfeng-Tongji cohort study of retired workers in Shiyan, Hubei province, China.
Ethical approval was obtained from the Medical Ethics Committee of the School of Public Health, Tongji Medical College, Huazhong University of Science and Technology.
Study population and design
We used data from Dongfeng-Tongji cohort (DFTJ cohort) study of retired workers, which was described in detail elsewhere . Briefly, this cohort was launched in 2008 among retirees of Dongfeng Motor Corporation (DMC) in Shiyan City, Hubei province, China. For the current study, we included 1177 documented CHD cases and 3531frequency-matched (by age and gender) controls between September 2008 and June 2010. CHD was confirmed on the basis of the most recent international guidelines: a combination of classical symptoms with positive results from 12-lead electrocardiograph (ECG), cardiac enzymes, functional or stress test, or coronary angiography using standard Judkins techniques (significant coronary artery stenoses≥50% in at least one major coronary artery) . A total of 55.73% (656) CHD cases underwent coronary angiography. Nonfatal myocardial infarction was diagnosed by a development of pathologic Q waves on serial ECG, elevations of cardiac enzyme values, or medical records for clinical symptoms and signs. 210 of CHD cases were diagnosed as MI according to their medical record.
Controls were randomly selected from retired employees employed in the same DFTJ cohort on the basis of medical history, clinical examinations, electrocardiography and face-to-face inquiry at admission. None of them had abnormalities of ECG or diagnostic evidence of CHD. Hypertension was defined as systolic/ diastolic blood pressure≥140/90mmHg in at least two measurements, or current use of anti-hypertensive medicine for the most recent 2 weeks, or a previous diagnosis of hypertension by a clinician. Diabetes mellitus (DM) was defined by the WHO criteria : fasting blood glucose (FBG)≥7mmol/L or a 2 hour postprandial plasma glucose ≥11.1mmol/L, or a prescription history of antidiabetic medications, including oral antidiabetics, incretin products, and insulin during the most previous two weeks, or a previous diagnosis of DM. Dyslipidemia was diagnosed as total cholesterol (TC) concentration≥5.72 mmol/L or triglyceride (TG) concentration ≥1.70 mmol/L or high-density lipoprotein cholesterol (HDL-C) concentration≤0.91mmol/L, or use medicine of dyslipidemia during the previous two weeks, or a positive history for dyslipidemia. All chronic diseases were verified through medical record reviews.
Subjects with a history of congenital heart disease, chronic heart failure, recent acute coronary syndrome (< 6 months), vascular disease, valvular disease, cardiomyopathy and neoplastic diseases and cancers were excluded through medical record review based on clinical symptoms, physical examination, electrocardiogram and chest X-ray.
After obtained written informed consent from every participant, a semi-structural questionnaire was used to collect baseline information by trained interviewers during face-to-face interviews. The medical examination was performed at the same time. Demographic information, socio-economic status, family and personal disease histories, medication history in recent two weeks, alcohol use and smoking consumption were also inquired in the questionnaire.
Educational levels were categorized as low (primary school or illiteracy), medium (junior high school) and high (senior high school, university or college or higher). Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.
After an overnight fast, five milliliters of fasting blood was drawn from all subjects with a vacuum coagulation tube for serum in the morning. We measured the serum CA-125 level with the ARCHITECT Ci8200 automatic analyzer (ABBOTT Laboratories. Abbott Park, Illinois, U.S.A.) using the Abbott Diagnostics reagents according to the manufacturer’s instructions at Dongfeng Central Hospital’s laboratory. The method used by the ARCITECT Ci8200 platform for serum CA-125 levels measurement is microparticle chemiluminescent immunoassay (CMIA).The intra-assay coefficients of variation were 5.50% for CA-125. Blood glucose and blood lipids (including TC, TG and HDL-C) measurements were described in our previous study .
Characteristics of study subjects are presented as mean (SD) for continuous variables and as percentages for categorical data. All continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. For serum CA-125 levels, the cut off values for division of data into concentration categories were based on the distribution in controls. Continuous variables were analyzed by 2-tailed t tests for normal distributions and the Mann-Whitney U test for nonparametric distributions. Categorical data were evaluated by Chi-square test as appropriate. Odds ratios and 95% confident intervals were estimated by logistic regression with and without adjustment for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction. All tests were two-sided and α < 0.05 was considered statistically significant. Analyses were performed using SPSS software (version 12.0; SPSS Inc., Chicago, IL, USA).
Characteristics of study population
The demographic characteristics of the study population are presented in Table 1. When compared with the controls, smoking (P < 0.001) and higher BMI (P < 0.001) were more common in cases while lower DBP (P < 0.001) and less drinking (P < 0.001) were found among cases. Total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) were lower in CHD cases than controls (P < 0.001). As expected, CHD patients were more likely to have hypertension, dyslipidemia and diabetes mellitus (P < 0.001, respectively). Pharmacological drugs (antibiotics, anticoagulant, anti-hypertensive and hypoglycemic drugs) were more often used in cases (P < 0.001, respectively). Median and range of CA-125 level were 7.60 U/ml (3.50-11.40 U/ml) in cases and 5.54 U/ml (1.31-9.90 U/ml) in controls. Serum CA-125 level was significantly higher in CHD cases than that in controls (P < 0.001).
|Demographic and risk factors||Cases (n = 1177)||Controls (n = 3531)||P-value|
|< 60||106 (9.01)||319 (9.03)|
|60-||566 (48.09)||1703 (48.23)|
|≥ 70||505 (42.91)||1509 (42.74)|
|Male||616 (52.34)||1853 (52.48)|
|Female||561 (47.66)||1678 (47.52)|
|Low||395 (33.85)||1149 (32.79)|
|High||370 (31.71)||1161 (33.13)|
|BMI (kg / m2)||< 0.001|
|< 23.9||371 (32.04)||1605 (46.44)|
|24-||552 (47.67)||1387 (40.13)|
|≥ 28||235 (20.29)||464 (13.43)|
|Physical activity||1043 (88.62)||3198 (90.57)||0.052|
|SBP||131.91 ± 17.36||131.29 ± 18.25||0.31|
|DBP||76.15 ± 10.47||77.35 ± 10.47||0.001|
|TC(mmol/L)||4.89 ± 1.14||5.21 ± 0.97||< 0.001|
|TG (mmol/L)||1.49 ± 0.95||1.43 ± 1.05||0.12|
|HDL (mmol/L)||1.34 ± 0.36||1.44 ± 0.41||< 0.001|
|Smoking status||< 0.001|
|Current||148 (12.60)||693 (19.73)|
|Former||277 (23.57)||415 (11.81)|
|Never||750 (63.83)||2405 (68.46)|
|Drinking status||< 0.001|
|Current||170 (14.46)||788 (22.32)|
|Former||133 (11.31)||159 (4.50)|
|Never||873 (74.23)||2583 (73.17)|
|Antibiotics||114 (9.69)||177 (5.01)||< 0.001|
|Anticoagulant||682 (57.94)||359 (10.17)||< 0.001|
|Anti-hypertensive medication||770 (65.42)||965 (27.33)||< 0.001|
|Hypoglycemic medication||257 (21.84)||346 (9.80)||< 0.001|
|Hypertension||942 (80.03)||1919 (54.35)||< 0.001|
|Diabetes mellitus||371 (31.52)||664 (18.80)||< 0.001|
|Dyslipidemia||905 (76.89)||1932 (54.72)||< 0.001|
|Family history of disease|
|Coronary heart disease||183 (15.55)||186 (5.27)||< 0.001|
|Myocardial infarction||38 (3.29)||32 (0.92)||< 0.001|
|CA-125 level (U/ml)||7.60 (3.50-11.40)||5.54 (1.31-9.90)||< 0.001*|
Serum CA-125 level and CHD risk
Analyses of CA-125 level in quartiles (Table 2) showed that the risk of CHD was doubled (OR: 2.10, 95%CI: 1.69-2.60) in the highest quartile of CA-125 level (CA-125≥9.90U/ml) compared to those in the lowest quartile (CA-125≤1.31U/ml). The risk among those in the third quartile (OR: 2.08) of CA-125 levels was similar to those in the fourth quartile (OR: 2.10). These two groups therefore were combined into a group as “high” CA-125 level and similarly, the first and the second quartiles were combined into the “low” CA-125 level group for further stratified analyses.
|Quartile||CA-125 level (U/ml)||Cases, n (%)||Controls, n (%)||OR (95% CI)||OR‡ (95% CI)|
|First||≤ 1.31||191 (16.23)||881 (24.95)||1.00||1.00|
|Second||1.31-5.54||215 (18.27)||884 (25.04)||1.12 (0.90-1.39)||1.11 (0.87-1.40)|
|Third||5.54-9.90||380 (32.29)||877 (24.84)||2.00 (1.64-2.44)||2.08 (1.67-2.58)|
|Fourth||≥ 9.90||391 (33.22)||889 (25.18)||2.03 (1.67-2.47)||2.10 (1.69-2.60)|
|Ptrend< 0.001||Ptrend< 0.001|
As shown in Table 3, the association between CA-125 level and CHD risk tended to be stronger among older persons (OR: 2.19, 95%CI: 1.75-2.73), males (OR: 2.07, 95%CI: 1.67-2.56) and overweight (OR: 2.03, 95%CI: 1.62-2.55) after adjustment for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction. The CHD risk was inclined to be stronger among current smokers (OR: 2.29, 95%CI: 1.50-3.49), current drinkers (OR: 2.35, 95%CI: 1.57-3.53) and persons with hypertension (OR: 2.04, 95%CI: 1.71-2.43), without diabetes mellitus (OR: 2.09, 95%CI: 1.75-2.50) and dyslipidemia (OR: 2.21, 95%CI: 1.66-2.95).
|Risk factors||Level§||Cases||Controls||Crude OR (95% CI)||OR# (95% CI)|
|High||55||156||1.13 (0.73-1.75)||1.44 (0.83-2.51)|
|High||365||808||2.01 (1.65-2.45)||2.19 (1.75-2.73)|
|High||351||802||2.01 (1.62-2.49)||2.00 (1.58-2.53)|
|High||418||955||1.99 (1.64-2.41)||2.07 (1.67-2.56)|
|High||353||811||1.81 (1.49-2.21)||1.96 (1.58-2.44)|
|High||244||798||1.94 (1.54-2.46)||2.00 (1.55-2.58)|
|High||363||695||1.91 (1.56-2.35)||2.03 (1.62-2.55)|
|High||156||245||1.80 (1.31-2.47)||1.93 (1.34-2.78)|
|High||98||333||2.12 (1.46-3.07)||2.29 (1.50-3.49)|
|High||187||227||1.72 (1.25-2.36)||1.93 (1.34-2.77)|
|High||486||1198||1.86 (1.57-2.20)||1.93 (1.60-2.33)|
|High||121||389||2.53 (1.77-3.63)||2.35 (1.57-3.53)|
|High||82||96||1.06 (0.66-1.69)||1.21 (0.69-2.12)|
|High||568||1280||1.90 (1.62-2.22)||2.05 (1.72-2.45)|
|High||612||910||2.06 (1.75-2.42)||2.04 (1.71-2.43)|
|High||159||856||1.85 (1.38-2.47)||1.91 (1.41-2.60)|
|High||591||974||1.85 (1.57-2.18)||1.91 (1.59-2.28)|
|High||180||792||1.99 (1.52-2.61)||2.21 (1.66-2.95)|
|High||248||380||1.51 (1.16-1.97)||1.59 (1.17-2.15)|
|High||523||1386||1.98 (1.68-2.32)||2.09 (1.75-2.50)|
We further analyzed serum CA-125 level and myocardial infarction (MI) risk in our population (Table S1), of the 210 CHD patients having MI, higher level of CA-125 was related to higher MI risk in a dose-responsive manner with adjustment for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction.
CA-125 level and the severity of coronary artery stenoses in CHD
We divided the 1177 CHD cases into two groups: CHD accompanying with MI (210, Table S1) and CHD without MI (967, Table S2), and then compared the two groups with controls (3531) respectively, the adjusted OR of CHD patients accompanying with MI in highest quartile of CA-125 level was 2.76 (95%CI: 1.73-4.41, P < 0.001), and that of CHD patients without MI was 2.02 (95%CI: 1.61-2.54, P < 0.001) after adjustment for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction.
Relation of CHD risk factors and serum CA-125 level among controls
Serum CA-125 level of controls ascended substantially with increasing age (Ptrend < 0.001; Table 4). Males tended to have higher serum CA-125 level than females (P = 0.015). Smokers had significantly higher CA-125 level than nonsmokers (P = 0.04). Controls with hypertension have significantly lower serum CA-125 level than those without hypertension (P = 0.001). Contrary results were found in controls with and without diabetes mellitus (P < 0.001). Controls taken hypoglycemic drugs tend to have significantly higher level of CA-125 (P = 0.03).
|Demographic and risk factors||N (n = 3531)||CA-125, mean ± SD (U/ml)||P-value|
|< 60||319||6.90 ± 8.34|
|60-||1703||6.25 ± 6.99|
|≥ 70||1509||7.04 ± 6.64|
|Male||1853||6.96 ± 7.69|
|Female||1678||6.30 ± 6.11|
|< 23.9||1605||6.55 ± 7.00|
|24-||1387||6.65 ± 7.29|
|≥ 28||464||7.03 ± 6.20|
|Yes||177||6.74 ± 6.96|
|No||3354||6.64 ± 6.99|
|Yes||359||7.10 ± 6.21|
|No||3172||6.60 ± 7.07|
|Yes||965||6.68 ± 6.00|
|No||2566||6.63 ± 7.33|
|Yes||346||7.17 ± 6.08|
|No||3185||6.59 ± 7.08|
|Current||693||6.69 ± 7.54|
|Former||415||7.62 ± 9.84|
|Never||2405||6.47 ± 6.19|
|Current||788||6.80 ± 7.24|
|Former||159||8.37 ± 13.75|
|Never||2583||6.49 ± 6.24|
|Yes||1919||6.36 ± 6.44|
|No||1612||6.99 ± 7.57|
|Yes||1932||6.84 ± 7.41|
|No||1599||6.40 ± 6.44|
|Diabetes mellitus||< 0.001|
|Yes||664||7.41 ± 6.26|
|No||2867||6.47 ± 7.14|
In this population-based case-control study, we investigated the association between serum CA-125 level and the risk of CHD in a large Chinese older population for the first time. We observed that the elevated serum CA-125 level was associated with a higher risk of CHD, and such associations were also evident in older individuals, males, current smokers and drinkers, overweight individuals, and those who had hypertension.
In early time, serum CA-125 was found to be related to diastolic and systolic parameters, ejection fraction and myocardial performance index in patients with chronic HF . Subsequently, elevated CA-125 level has also been observed in other cardiac pathologies such as aortic stenosis, mitral stenosis, mitral valve endocarditis, acute myocardial infarction [32-36]. However, in stark contrast, little data has been published concerning the association of the concentration of serum CA-125 and CHD risk until now.
As to the possible mechanisms involved in increased CA-125 level observed in HF, De Gennaro et al. suggested that haemodynamic abnormalities and inflammatory cytokines may play significant roles in the development of atherosclerosis and its complications . A few later studies have also demonstrated that CA-125 is expressed in different tissues derived from coelomic epithelium in response to various stimuli, including mechanical stress and inflammatory stimuli [38-41]. Furthermore, under normal circumstances, mesothelial cells could maintain a steady-state with proliferation balanced by cell death. However, such balance is disrupted when mesothelial cells are exposed to mechanical stress and inflammatory stimuli in the early phase of atherosclerosis. On the one hand, mesothelial cells might synthesize more hyaluronan and cytoplasmic fibers to defense the cellular injury and death [42,43]. Vitro experiments have demonstrated that the secretion of CA-125 could be enhanced by the inflammatory cytokines . So inflammatory may be responsible for serum CA-125 role in CHD development. Our findings suggested that serum CA-125 was related to some inflammatory related status, such as smoking, hypertension and diabetes mellitus, may act as an evidence to support this hypothesis.
In our study, CA-125 level-associated CHD risks were higher in subjects aged over 60 years, overweight individuals, cigarette smoke and hypertension. The similar results have been found in the PLCO (Prostate, Lung, Colorectal and Ovarian Cancer) screening trial  except for subjects with hypertension. These factors may damage the endothelium and lead to the subsequent inflammatory reactions in the vascular wall, which in turn increases the production of primary proinflammatory cytokines . The association of higher CA-125 level with higher CHD risk in older age could possibly be a consequence of aging processes at the cellular and immunological level . Cigarette smoke is a major risk factor for CHD and produces a chronic inflammatory state that contributes to the atherogenic disease processes and elevates levels of biomarkers of inflammation. Besides, this chronic state of inflammation might be directly related to subsequent elevated risk for cardiovascular diseases and has detrimental effects on the metabolism and function of innate immune cells [47,48]. The plausibility is supported by our observation that among controls smokers tended to have higher level of serum CA-125 than nonsmokers.
An inverse correlation between CA-125 level and metabolic syndrome was recently reported in a study including 12,196 healthy Korean women . Similar results have been also found in the present study. For example, controls with hypertension had significantly lower serum CA-125 level than those without hypertension. While conflicting findings showed that serum CA-125 levels were associated with lower risks of CHD in patients with dyslipdemia and diabetes mellitus after adjustment with confounding factors. That may be due to the different doses and/or the duration of the medicines they taken. However, the precise mechanisms should be investigated in future prospective studies.
In terms of limitations, the current case-control design limits the causal interpretation of the relationship between serum CA-125 level and the risk of coronary heart disease because the blood samples were collected from subjects having CHD events. Another limitation is that some CHD cases took multiple medications, which acted as a confounding factor when we analyzed the relationship between CA-125 level and CHD risk by subgroups. Thus, such findings need to be validated by future large prospective investigations. Furthermore, the role of unmeasured or residual confounding could not be ignored although we have adjusted for a wide range of CHD risk factors. Nevertheless, this is the first study to examine the association between serum CA-125 level and the risk of CHD in a large Chinese older population. Secondly, the sample size is considerable, which allows us to investigate the association between increased CA-125 level and CHD risk.
In summary, our findings suggested that higher serum CA-125 level might be associated with a significantly increased risk of CHD in Chinese older population. Future prospective studies should be motivated by this finding to explore the precise mechanisms.
The association between CA-125 level and CHD with nonfatal MI in Chinese older population.
We thank all study participants and staffs of the Health Examination Center of the Dongfeng Central Hospital and the Medical Insurance Center of DMC for their generous help. We also thank the interviewers from the retirement management office of DMC and from Tongji Medical College, HUST.
Conceived and designed the experiments: FBH TCW HDY. Performed the experiments: JZ PY XLL MJL XWM JY SW. Analyzed the data: SW MAH XRL. Wrote the manuscript: XRL.
- 1. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S (1993) CA 125 in gynecological pathology--a review. Eur J Obstet Gynecol Reprod Biol 49: 115-124. doi:https://doi.org/10.1016/0028-2243(93)90135-Y. PubMed: 8365505.
- 2. Sikaris KA (2011) CA125--a test with a change of heart. Heart Lung Circ 20: 634-640. doi:https://doi.org/10.1016/j.hlc.2010.08.001. PubMed: 20822954.
- 3. Saygili U, Guclu S, Uslu T, Erten O, Dogan E (2002) The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer 12: 438-442. doi:https://doi.org/10.1046/j.1525-1438.2002.01171.x. PubMed: 12366659.
- 4. Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y et al. (2002) Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 85: 108-113. doi:https://doi.org/10.1006/gyno.2001.6575. PubMed: 11925128.
- 5. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD et al. (2005) The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7: 199-203. doi:https://doi.org/10.1016/j.ejheart.2004.07.015. PubMed: 15701467.
- 6. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G et al. (2003) Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41: 1805-1811. doi:https://doi.org/10.1016/S0735-1097(03)00311-5. PubMed: 12767668.
- 7. Varol E, Ozaydin M, Dogan A, Kosar F (2005) Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7: 840-843. doi:https://doi.org/10.1016/j.ejheart.2004.12.008. PubMed: 15916923.
- 8. De Gennaro L, Brunetti ND, Bungaro R, Montrone D, Cuculo A et al. (2009) Carbohydrate antigen-125: additional accuracy in identifying patients at risk of acute heart failure in acute coronary syndrome. Coron Artery Dis 20: 274-280. doi:https://doi.org/10.1097/MCA.0b013e3283229d82. PubMed: 19440066.
- 9. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C et al. (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24: 172-175. doi:https://doi.org/10.1159/000074425. PubMed: 14654710.
- 10. Varol E, Ozaydin M, Altinbas A, Aslan SM, Dogan A et al. (2007) Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels 22: 30-33. doi:https://doi.org/10.1007/s00380-006-0938-9. PubMed: 17285443.
- 11. Ragni T, Da Col U, Di Manici G, Di Bella I, Di Lazzaro D et al. (2003) A case of pseudoaneurysm of the left ventricular lateral wall. Diagnosis and surgical treatment. Ital Heart J Suppl 4: 340-343. PubMed: 12784770.
- 12. Yanada M, Shimada J, Ito K, Terauchi K, Shimomura M (2007) Cardiac angiosarcoma with diagnostic difficulty. Kyobu Geka 60: 1148-1151. PubMed: 18078079.
- 13. Chelbi F , Hamzaoui A , Kacem M , Hammami S , Mahjoub S (2002) Increase of CA-125 in pericardial tamponade. Presse Med 31: 1366. PubMed: 12375390.
- 14. Rostoff P, Mroczek-Czernecka D, Piwowarska W (2008) Elevated CA-125 level in acute heart failure due to Toxoplasma gondii perimyocarditis. Int J Cardiol 130: e114-e116. doi:https://doi.org/10.1016/j.ijcard.2007.07.018. PubMed: 17689762.
- 15. De Gennaro L, Brunetti ND, Montrone D, De Rosa F, Cuculo A et al. (2012) Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation. Eur J Clin Invest 42: 371-375. doi:https://doi.org/10.1111/j.1365-2362.2011.02592.x. PubMed: 21913917.
- 16. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S et al. (2010) Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 121: e46-e215. doi:https://doi.org/10.1161/CIRCULATIONAHA.109.192667. PubMed: 20019324.
- 17. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD et al. (2011) Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 123: e18-e209. doi:https://doi.org/10.1161/CIR.0b013e3182009701. PubMed: 21160056.
- 18. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD et al. (2012) Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 125: e2-e220. doi:https://doi.org/10.1161/CIR.0b013e31823ac046. PubMed: 22179539.
- 19. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442. doi:https://doi.org/10.1371/journal.pmed.0030442. PubMed: 17132052.
- 20. Ross R (1999) Atherosclerosis--an inflammatory disease. N Engl J Med 340: 115-126. doi:https://doi.org/10.1056/NEJM199901143400207. PubMed: 9887164.
- 21. Wick G, Knoflach M, Xu Q (2004) Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 22: 361-403. doi:https://doi.org/10.1146/annurev.immunol.22.012703.104644. PubMed: 15032582.
- 22. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874. doi:https://doi.org/10.1038/nature01323. PubMed: 12490960.
- 23. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES et al. (2008) Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 47: 3-7. doi:https://doi.org/10.1093/rheumatology/kem202. PubMed: 17702769.
- 24. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM et al. (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112: 3337-3347. doi:https://doi.org/10.1161/CIRCULATIONAHA.104.507996. PubMed: 16301360.
- 25. Righi L, Volante M, Rapa I, Tavaglione V, Inzani F et al. (2010) Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 17: 977-987. doi:https://doi.org/10.1677/ERC-10-0157. PubMed: 20817788.
- 26. Epiney M, Bertossa C, Weil A, Campana A, Bischof P (2000) CA125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 15: 1261-1265. doi:https://doi.org/10.1093/humrep/15.6.1261. PubMed: 10831552.
- 27. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E (2006) Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 8: 270-274. doi:https://doi.org/10.1016/j.ejheart.2005.09.002. PubMed: 16309955.
- 28. Wang F, Zhu J, Yao P, Li X, He M et al. (2013) Cohort profile: The Dongfeng-Tongji cohort study of retired workers. Int J Epidemiol, 42: 731–40. PubMed: 22531126.
- 29. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC et al. (2012) 2012ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and managementof patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association forThoracic Surgery, Preventive Cardiovascular Nurses Association, Society forCardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol18;60Volumes 24: e44-e164.
- 30. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33 Suppl 1: S62-S69. doi:https://doi.org/10.2337/dc10-S062. PubMed: 20042775.
- 31. Vizzardi E, Nodari S, D'Aloia A, Chiari E, Faggiano P et al. (2008) CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. Echocardiography 25: 955-960. doi:https://doi.org/10.1111/j.1540-8175.2008.00714.x. PubMed: 18771557.
- 32. Antonini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R et al. (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128: 406-412. doi:https://doi.org/10.1016/j.ijcard.2007.05.039. PubMed: 17662495.
- 33. Duman C, Ercan E, Tengiz I, Bozdemir H, Ercan HE et al. (2003) Elevated serum CA 125 levels in mitral stenotic patients with heart failure. Cardiology 100: 7-10. doi:https://doi.org/10.1159/000072385. PubMed: 12975539.
- 34. Yalta K, Yilmaz A, Turgut OO, Erselcan T, Yilmaz MB et al. (2006) Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction. Adv Ther 23: 1052-1059. doi:https://doi.org/10.1007/BF02850225. PubMed: 17276972.
- 35. Sugishita H, Imagawa H, Kawachi K,Takano S, Tsunooka N et al. (2005) Normalization of cancer antigen 125 after mitral valve replacement in a patient with congestive heart failure due to mitral valve endocarditis. Jpn J Thorac Cardiovasc Surg 53: 486-489. doi:https://doi.org/10.1007/s11748-005-0092-9. PubMed: 16200889.
- 36. Varol E, Yücel H, Arslan A, Ozaydın M, Erdoğan D et al. (2012) Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars 40: 309-315. doi:https://doi.org/10.5543/tkda.2012.87894. PubMed: 22951846.
- 37. Ozeren A, Aydin M, Tokac M, Demircan N, Unalacak M et al. (2003) Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris. Mediators Inflamm 12: 361-365. doi:https://doi.org/10.1080/09629350310001633360. PubMed: 14668096.
- 38. Huang F, Chen J, Liu Y, Zhang K, Wang J et al. (2012) New mechanism of elevated CA125 in heart failure: The mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses 26: 26. PubMed: 22743023.
- 39. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z et al. (1998) CA 125: the past and the future. Int J Biol Markers 13: 179-187. PubMed: 10228898.
- 40. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC et al. (1983) Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2: 275-285. doi:https://doi.org/10.1097/00004347-198303000-00005. PubMed: 6196309.
- 41. Turgut O, Tandogan I, Yilmaz MB, Gul I, Zorlu A (2011) CA125 in heart failure: implications for immunoinflammatory activity. Int J Cardiol 146: 99-100. doi:https://doi.org/10.1016/j.ijcard.2010.05.077. PubMed: 20580098.
- 42. Leard LE, Broaddus VC (2002) Mesothelial cells: their structure, function and role in serosal repair. Respirology 7: 171-191. doi:https://doi.org/10.1046/j.1440-1843.2002.00404.x. PubMed: 12153683.
- 43. Leard LE, Broaddus VC (2004) Mesothelial cell proliferation and apoptosis. Respirology 9: 292-299. doi:https://doi.org/10.1111/j.1440-1843.2004.00602.x. PubMed: 15362999.
- 44. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P (1994) CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 47: 263-265. doi:https://doi.org/10.1136/jcp.47.3.263. PubMed: 8163699.
- 45. Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR et al. (2008) The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol 110: 383-389. doi:https://doi.org/10.1016/j.ygyno.2008.05.006. PubMed: 18586313.
- 46. El-Mesallamy HO, Hamdy NM, Salman TM, Ibrahim SM (2012) Adiponectin and sE-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease. Angiology 63: 96-102. doi:https://doi.org/10.1177/0003319711408587. PubMed: 21602254.
- 47. Csordas A, Wick G, Laufer G, Bernhard D (2008) An Evaluation of the Clinical Evidence on the Role of Inflammation and Oxidative Stress in Smoking-Mediated Cardiovascular Disease. Biomark Insights 3: 127-139. PubMed: 19578488.
- 48. Wright WR, Parzych K, Crawford D, Mein C, Mitchell JA et al. (2012) Inflammatory transcriptome profiling of human monocytes exposed acutely to cigarette smoke. PLOS ONE 7: e30120. doi:https://doi.org/10.1371/journal.pone.0030120. PubMed: 22363418.
- 49. Joo NS, Kim KN, Kim KS (2011) Serum CA125 concentration has inverse correlation with metabolic syndrome. J Korean Med Sci26(10): 1328-1332. doi:https://doi.org/10.3346/jkms.2011.26.10.1328. PubMed: 22022186.